| Name | Title | Contact Details |
|---|
TVG-Medulla, LLC (Medulla) is a wellness-focused healthcare management organization providing incomparable support and services to more than 40 Chiro One Wellness Center locations. In addition to our full-scale management departments and a wide-range of Medulla career opportunities, Medulla also offers engaging wellness programs and education services to communities, employers and organizations across Chicagoland.
Renue Physical Therapy was established in the Fall of 2011 with one clinic on Bay Road in Saginaw. Our goal from the start was to create a fully patient-focused practice model. We take pride in offering one-on-one treatment with the same therapy team throughout the course of therapy, providing a customized plan that is specific to your needs to help you achieve the best possible outcomes. Since our start in 2011, Renue has grown to more than 12 clinics serving the Great Lakes Bay Region and beyond, with locations in Auburn, Au Gres, Bay City, Bridgeport, Caro, Freeland, Midland, Saginaw and Shields.
Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara`s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
STATPROBE, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.